Mold-Tek’s Pharma Breakthrough: Eyes ₹30 Cr Revenue Surge in FY26

Image Source: BizzBuzz.news

Mold-Tek Packaging has achieved a major milestone in its pharmaceutical packaging division, crossing the breakeven point in Q4 FY25. The company now expects ₹30 crore in revenue from pharma sales in FY26, driven by new product launches and rising demand.

The pharma segment, which contributed ₹6.7 crore in Q4 FY25, is projected to hit ₹50 crore by FY27, as Mold-Tek expands its injection molding capacity. The company is investing ₹10 crore in facility expansion in Sultanpur, Hyderabad, doubling its production capacity from 1,500 to 3,000 tons.

Additionally, the paint division has rebounded with 6.8% growth, supported by new contracts from Aditya Birla Group and Asian Paints. Mold-Tek is also expanding into the food and FMCG sector, with Panipat production starting in June 2025, adding Mankind Pharma and Marico as key clients.

Key Highlights:

Mold-Tek’s pharma division crosses breakeven, targets ₹30 crore revenue in FY26.
Facility expansion in Hyderabad to double production capacity.
Paint division sees 6.8% growth, securing major corporate contracts.
Food & FMCG expansion with new clients like Mankind Pharma & Marico.

Source: Sunday Guardian | GuruFocus | Market Setup